Markets:

Overview

News

Currencies

International

Treasuries

Aclaris Therapeutics, Inc. - Common Stock (NQ:ACRS)

2.525 -0.115 (-4.36%)

Streaming Delayed Price Updated: 10:24 AM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Aclaris Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus ↗

July 30, 2025

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher.

Via Benzinga

Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement ↗

July 30, 2025

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from its open-label Phase 2a trial.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 29, 2025

Via Benzinga

What's going on in today's after hours session ↗

July 29, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Aclaris Therapeutics: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Aclaris Therapeutics ↗

January 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 28, 2025

Via Benzinga

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 28, 2025

Via Benzinga

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy ↗

December 23, 2024

HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and...

Via Benzinga

Santa Rally, January Effect, And Top Stock Picks ↗

December 23, 2024

Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas!

Via Talk Markets

Topics Stocks / Equities

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday ↗

December 23, 2024

Via Benzinga

Level Up Your Trading: Inside The 4-Pillar Strategy Behind Triple-Digit Returns ↗

December 18, 2024

Explore market insights and top picks with our 4-pillar strategy.

Via Talk Markets

Topics Stocks / Equities

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments ↗

November 19, 2024

Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.

Via Benzinga

War, Gold, And Opportunity: Uncovering Today’s Market Moves ↗

November 19, 2024

Geopolitical tensions drive market moves as we analyze top picks.

Via Talk Markets

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

November 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 25, 2024

Via Benzinga

Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying ↗

July 23, 2024

Via Benzinga

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying ↗

July 08, 2024

Via Benzinga

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

June 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 24, 2024

Via Benzinga

ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

ACRS stock results show that Aclaris Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying ↗

March 06, 2024

The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades ↗

January 22, 2024

HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.

Via Benzinga

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 22, 2024

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...

Via Benzinga

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket ↗

January 22, 2024

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 16, 2024

Via Benzinga

Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today? ↗

January 16, 2024

Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris...

Via Benzinga

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations ↗

January 10, 2024

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Aclaris Therapeutics, Inc. - Common Stock (NQ:ACRS)

Headline News about Aclaris Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today